[EN] 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD [FR] 2-PYRAZOLE ANILINES ET ANALOGUES APPARENTÉS POUR INHIBER YAP/TAZ-TEAD
摘要:
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
[EN] PYRAZOLE DERIVATIVES AS SGC STIMULATORS<br/>[FR] DÉRIVÉS DE PYRAZOLE UTILISÉS COMME STIMULATEURS DE SGC
申请人:IRONWOOD PHARMACEUTICALS INC
公开号:WO2016044447A1
公开(公告)日:2016-03-24
There are described imidazole and pyrazole derivatives which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
Trifluoromethylation of aromatic and hetero-aromatic compounds by CF3I in the presence of Fe(II) compound, H2O2 and dimethylsulfoxide was investigated. Various trifluoromethylated benzene derivatives, six-membered nitrogen-containing aromaticcompounds and five-membered hetero-aromatic compounds were obtained under mild conditions. General orientation of electrophilic substitution of aromaticcompounds was observed
研究了在Fe(II)化合物,H 2 O 2和二甲基亚砜的存在下,CF 3 I对芳族和杂芳族化合物的三氟甲基化作用。在温和条件下获得了各种三氟甲基化苯衍生物,六元含氮芳族化合物和五元杂芳族化合物。与先前在其他自由基三氟甲基化中报道的类似,观察到芳族化合物的亲电子取代的一般取向。
[EN] INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP)<br/>[FR] INHIBITEURS DE LA PROTÉINE DE LIAISON AUX ACIDES GRAS (FABP)
申请人:SCHERING CORP
公开号:WO2010056631A1
公开(公告)日:2010-05-20
The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein ("FABP") inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the present invention is shown below: (I)
Access to azolopyrimidine-6,7-diamines as a valuable “building-blocks” to develop new fused heteroaromatic systems
作者:Denis A. Gazizov、Victor V. Fedotov、Konstantin A. Chistyakov、Evgeny B. Gorbunov、Gennady L. Rusinov、Valery N. Charushin
DOI:10.1016/j.tet.2021.132172
日期:2021.6
A simple and convenient approach for the synthesis of new azolopyrimidine-6,7-diamines has been developed by the method of reductive cleavage of azo-group in series 6-[2-(4-methylphenyl)diazenyl]azolo[1,5-a]pyrimidine-7-amines, which was obtained by the interaction of aminoazoles with [2-(4-methylphenyl)hydrazinylidene]-3-oxo-propionitrile. The proposed approach allows to use a wide range of aminoazoles
通过还原裂解 6-[2-(4-甲基苯基)二氮烯基]唑并[1,5-]系列中的偶氮基团的方法,开发了一种简单方便的合成新型唑并嘧啶-6,7-二胺的方法。a ]嘧啶-7-胺,它是通过氨基唑与[2-(4-甲基苯基)肼基]-3-氧代-丙腈相互作用获得的。所提出的方法允许使用范围广泛的氨基唑作为起始试剂,并且它还通过产品分离和纯化的简单性而与众不同。通过获得唑并[ a ]环化蝶啶的反应证明了所呈现的二胺的合成潜力。